Novartis heavyweight anti-inflammatory drug cosentyx is approved by nice in the UK

Source: Sina pharmaceutical 2017-04-20 Swiss pharmaceutical giant Novartis heavy anti-inflammatory drug cosentityx (secukinumab) recently received good news in the UK regulation The National Institute of health and Clinical Excellence (NICE) has issued a final assessment decision (FAD) to support the use of cosentyx in the NHS for the treatment of active, progressive psoriatic arthritis (PSA) in adults PSA is a common inflammatory joint disease associated with psoriasis It has psoriasis rash accompanied by pain, swelling, tenderness, stiffness and movement disorders of joints and surrounding soft tissues Some patients may have sacroiliac arthritis and / or spondylitis The course of disease is prolonged, easy to recur, and joint rigidity may occur in the later stage The disease can occur at any age, the peak age is 40-50 years old, there is no sex difference, but the spine is more affected by men If not effectively treated, chronic inflammation will lead to irreversible joint and / or spinal injury, lead to lifelong pain and disability, and have a serious negative impact on patients' daily life It is estimated that about 117000 people in the UK are suffering from PSA At present, anti-tumor necrosis factor (anti-TNF) therapy has been used as a standard nursing therapy in the treatment of PSA, but as high as 30% - 40% of patients lack of remission Therefore, there are clear unmet medical needs in this field Cosentix will provide an important new treatment option for these patients Specifically, nice recommends cosentyx for psoriatic arthritis patients with peripheral arthritis who have 3 or more joint tenderness and 3 or more joint swelling and who do not respond adequately to at least 2 disease modifying antirheumatic drugs (DMARDs, administered in single or combination) At the same time, cosentyx is also suitable for psoriatic arthritis patients who have received tumor necrosis factor - α (TNF - α) inhibitor treatment before but have no remission in the first 12 weeks of treatment or stop remission after 12 weeks of treatment, or are not suitable for the treatment of such drugs due to the taboo of TNF - α inhibitor Cosentyx is the first monoclonal antibody against IL-17 in the world It was approved by the United States and the European Union in January 2015 It is a first-line treatment for adult patients with moderate to severe plaque psoriasis This approval marks a major milestone in the clinical treatment of psoriasis In November 2015 and January 2016, cosentix was approved by the United States and the European Union for two new indications: ankylosing spondylitis (as) and psoriatic arthritis (PSA) This approval also marks that cosentix is the first and only IL-17 monoclonal antibody that can be used to treat two of the most common inflammatory joint diseases (as and PSA), and also marks that cosentix is the successor The first breakthrough in the clinical treatment of as has been made 16 years since the introduction of TNF McAb In the UK, cosentix was approved by nice in July 2015 for patients with moderate to severe plaque psoriasis; in August 2016, cosentix was again approved by nice for patients with active ankylosing spondylitis (as) who had previously received non steroidal anti-inflammatory drugs or TNF - α inhibitors with poor control or were not suitable for these drugs Cosentyx is a humanized monoclonal antibody, which can selectively target to block the activity of circulating IL-17A, reduce the activity of the immune system and improve the symptoms of the disease It is revealed that IL-17A plays an important role in the immune response of plaque psoriasis, ankylosing spondylitis (as) and psoriatic arthritis (PSA) In clinical trials, cosentyx significantly improved the symptoms and signs of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis compared with placebo and control drugs Article reference source: nice nod for Novartis' cosentix in PSA